polatuzumab vedotin + rituximab + lenalidomide
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for polatuzumab vedotin + rituximab + lenalidomide, covering 2023-12-26 to 2023-12-26. Get the full timeline:
Most recent: Clinical Trial Update: A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 1, Phase 2]